# A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

> **NCT05603052** · PHASE3 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 2852 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** EuCorVac-19
- **BIOLOGICAL:** ChAdOx1 nCoV-19

## Key facts

- **NCT ID:** NCT05603052
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-11
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 2852 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603052, "A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05603052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*